(R)-2-hydroxy-1-(4-(5-(3-phenoxy-5-(pyridin-2-ylthio)pyridin-2-ylamino)-1,2,4-thiadiazol-3-yl)piperidin-1-yl)propan-1-one | 953043-07-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (R)-2-hydroxy-1-(4-(5-(3-phenoxy-5-(pyridin-2-ylthio)pyridin-2-ylamino)-1,2,4-thiadiazol-3-yl)piperidin-1-yl)propan-1-one
• 英文别名: (2R)-2-hydroxy-1-[4-[5-[(3-phenoxy-5-pyridin-2-ylsulfanylpyridin-2-yl)amino]-1,2,4-thiadiazol-3-yl]piperidin-1-yl]propan-1-one
• CAS: 953043-07-7
• 化学式: C₂₆H₂₆N₆O₃S₂
• 分子量: 534.663
• InChiKey: OGTIVLDRXVBTPJ-QGZVFWFLSA-N

物化性质

• 沸点：
  762.1±70.0 °C(Predicted)
• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  37
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  167
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  3-苯氧基吡啶-2-胺 在 4-二甲氨基吡啶 吡啶 、 盐酸 、 甲基锂 、 溴 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 氯仿 、 乙腈 为溶剂， 反应 5.92h， 生成 (R)-2-hydroxy-1-(4-(5-(3-phenoxy-5-(pyridin-2-ylthio)pyridin-2-ylamino)-1,2,4-thiadiazol-3-yl)piperidin-1-yl)propan-1-one
  参考文献：
  名称：

  WO2008/118718

  摘要：

  公开号：

文献信息

• 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS
  申请人：Aicher Thomas D.

  公开号：US20090156603A1

  公开（公告）日：2009-06-18

  Provided are compounds of formula I that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes meilitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

  提供了化学式I的化合物，这些化合物在治疗和/或预防由胰岛素活性不足引起的疾病中非常有用，例如糖尿病。还提供了治疗或预防由胰岛素活性不足或可以通过激活胰岛素来治疗的疾病和疾患的方法。
• 2-aminopyridine analogs as glucokinase activators
  申请人：Aicher Thomas Daniel

  公开号：US08362037B2

  公开（公告）日：2013-01-29

  Provided are compounds that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

  提供了一些化合物，这些化合物在治疗和/或预防由葡萄糖激酶活性不足引起的疾病（如糖尿病）方面非常有用。同时还提供了治疗或预防由葡萄糖激酶活性不足或可以通过激活葡萄糖激酶来治疗的疾病和疾病的方法。
• Discovery and preclinical development of AR453588 as an anti-diabetic glucokinase activator
  作者：Ronald J. Hinklin、Brian R. Baer、Steven A. Boyd、Mark D. Chicarelli、Kevin R. Condroski、Walter E. DeWolf、John Fischer、Michele Frank、Gary P. Hingorani、Patrice A. Lee、Nickolas A. Neitzel、Scott A. Pratt、Ajay Singh、Francis X. Sullivan、Timothy Turner、Walter C. Voegtli、Eli M. Wallace、Lance Williams、Thomas D. Aicher

  DOI：10.1016/j.bmc.2019.115232

  日期：2020.1

  Glucose flux through glucokinase (GK) controls insulin release from the pancreas in response to high levels of glucose. Flux through GK is also responsible for reducing hepatic glucose output. Since many individuals with type 2 diabetes appear to have an inadequacy or defect in one or both of these processes, identifying compounds that can activate GK could provide a therapeutic benefit. Herein we report the further structure activity studies of a novel series of glucokinase activators (GKA). These studies led to the identification of pyridine 7 2 as a potent GKA that lowered post-prandial glucose in normal C57BL/6J mice, and after 14d dosing in ob/ob mice.
• A method of preparing 2-aminopyridine analogs as glucokinase activators
  申请人：Array Biopharma, Inc.

  公开号：EP2543667B1

  公开（公告）日：2015-01-28
• US8022223B2
  申请人：——

  公开号：US8022223B2

  公开（公告）日：2011-09-20